Literature DB >> 22632792

Inhibitors of Dengue virus and West Nile virus proteases based on the aminobenzamide scaffold.

Sridhar Aravapalli1, Huiguo Lai, Tadahisa Teramoto, Kevin R Alliston, Gerald H Lushington, Eron L Ferguson, R Padmanabhan, William C Groutas.   

Abstract

Dengue and West Nile viruses (WNV) are mosquito-borne members of flaviviruses that cause significant morbidity and mortality. There is no approved vaccine or antiviral drugs for human use to date. In this study, a series of functionalized meta and para aminobenzamide derivatives were synthesized and subsequently screened in vitro against Dengue virus and West Nile virus proteases. Four active compounds were identified which showed comparable activity toward the two proteases and shared in common a meta or para(phenoxy)phenyl group. The inhibition constants (K(i)) for the most potent compound 7n against Dengue and West Nile virus proteases were 8.77 and 5.55 μM, respectively. The kinetics data support a competitive mode of inhibition of both proteases by compound 7n. This conclusion is further supported by molecular modeling. This study reveals a new chemical scaffold which is amenable to further optimization to yield potent inhibitors of the viral proteases via the combined utilization of iterative medicinal chemistry/structure-activity relationship studies and in vitro screening.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22632792      PMCID: PMC3563422          DOI: 10.1016/j.bmc.2012.04.055

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  38 in total

1.  Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries.

Authors:  Jun Li; Siew Pheng Lim; David Beer; Viral Patel; Daying Wen; Christine Tumanut; David C Tully; Jennifer A Williams; Jan Jiricek; John P Priestle; Jennifer L Harris; Subhash G Vasudevan
Journal:  J Biol Chem       Date:  2005-06-01       Impact factor: 5.157

2.  A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease.

Authors:  Christophe Bodenreider; David Beer; Thomas H Keller; Sebastian Sonntag; Daying Wen; Lijian Yap; Yin Hoe Yau; Susana Geifman Shochat; Danzhi Huang; Ting Zhou; Amedeo Caflisch; Xun-Cheng Su; Kiyoshi Ozawa; Gottfried Otting; Subhash G Vasudevan; Julien Lescar; Siew Pheng Lim
Journal:  Anal Biochem       Date:  2009-08-13       Impact factor: 3.365

Review 3.  The medicinal chemistry of dengue fever.

Authors:  Andrew J Stevens; Michelle E Gahan; Suresh Mahalingam; Paul A Keller
Journal:  J Med Chem       Date:  2009-12-24       Impact factor: 7.446

4.  Small molecule pan-dengue and West Nile virus NS3 protease inhibitors.

Authors:  Lynne Cregar-Hernandez; Guan-Sheng Jiao; Alan T Johnson; Axel T Lehrer; Teri Ann S Wong; Stephen A Margosiak
Journal:  Antivir Chem Chemother       Date:  2011-05-12

5.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

6.  Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation.

Authors:  Pornwaratt Niyomrattanakit; Pakorn Winoyanuwattikun; Santad Chanprapaph; Chanan Angsuthanasombat; Sakol Panyim; Gerd Katzenmeier
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

7.  Modulation of the nucleoside triphosphatase/RNA helicase and 5'-RNA triphosphatase activities of Dengue virus type 2 nonstructural protein 3 (NS3) by interaction with NS5, the RNA-dependent RNA polymerase.

Authors:  Changsuek Yon; Tadahisa Teramoto; Niklaus Mueller; Jessica Phelan; Vannakambadi K Ganesh; Krishna H M Murthy; R Padmanabhan
Journal:  J Biol Chem       Date:  2005-05-24       Impact factor: 5.157

8.  Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction.

Authors:  Kanin Wichapong; Somsak Pianwanit; Wolfgang Sippl; Sirirat Kokpol
Journal:  J Mol Recognit       Date:  2010 May-Jun       Impact factor: 2.137

Review 9.  Strategies for development of Dengue virus inhibitors.

Authors:  Christian G Noble; Yen-Liang Chen; Hongping Dong; Feng Gu; Siew Pheng Lim; Wouter Schul; Qing-Yin Wang; Pei-Yong Shi
Journal:  Antiviral Res       Date:  2010-01-08       Impact factor: 5.970

10.  Histone deacetylase inhibitors through click chemistry.

Authors:  Jie Shen; Robert Woodward; James Patrick Kedenburg; Xianwei Liu; Min Chen; Lanyan Fang; Duxin Sun; Peng George Wang
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

View more
  12 in total

1.  C-terminal residue optimization and fragment merging: discovery of a potent Peptide-hybrid inhibitor of dengue protease.

Authors:  Mira A M Behnam; Christoph Nitsche; Sérgio M Vechi; Christian D Klein
Journal:  ACS Med Chem Lett       Date:  2014-07-18       Impact factor: 4.345

2.  Undersampling: case studies of flaviviral inhibitory activities.

Authors:  Stephen J Barigye; José Manuel García de la Vega; Juan A Castillo-Garit
Journal:  J Comput Aided Mol Des       Date:  2019-11-26       Impact factor: 3.686

Review 3.  Targeting the protease of West Nile virus.

Authors:  Saan Voss; Christoph Nitsche
Journal:  RSC Med Chem       Date:  2021-05-26

4.  Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases.

Authors:  Huiguo Lai; Dengfeng Dou; Sridhar Aravapalli; Tadahisa Teramoto; Gerald H Lushington; Tom M Mwania; Kevin R Alliston; David M Eichhorn; Radhakrishnan Padmanabhan; William C Groutas
Journal:  Bioorg Med Chem       Date:  2012-11-15       Impact factor: 3.641

5.  Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection.

Authors:  Jacob Nelson; Kelsey Roe; Beverly Orillo; Pei-Yong Shi; Saguna Verma
Journal:  Antiviral Res       Date:  2015-07-29       Impact factor: 5.970

Review 6.  The flavivirus protease as a target for drug discovery.

Authors:  Matthew Brecher; Jing Zhang; Hongmin Li
Journal:  Virol Sin       Date:  2013-11-14       Impact factor: 4.327

7.  Discovery of novel West Nile Virus protease inhibitor based on isobenzonafuranone and triazolic derivatives of eugenol and indan-1,3-dione scaffolds.

Authors:  André S de Oliveira; Poliana A R Gazolla; Ana Flávia C da S Oliveira; Wagner L Pereira; Lívia C de S Viol; Angélica F da S Maia; Edjon G Santos; Ítalo E P da Silva; Tiago A de Oliveira Mendes; Adalberto M da Silva; Roberto S Dias; Cynthia C da Silva; Marcelo D Polêto; Róbson R Teixeira; Sergio O de Paula
Journal:  PLoS One       Date:  2019-09-26       Impact factor: 3.240

8.  Thioguanine-based DENV-2 NS2B/NS3 protease inhibitors: Virtual screening, synthesis, biological evaluation and molecular modelling.

Authors:  Maywan Hariono; Sy Bing Choi; Ros Fatihah Roslim; Mohamed Sufian Nawi; Mei Lan Tan; Ezatul Ezleen Kamarulzaman; Nornisah Mohamed; Rohana Yusof; Shatrah Othman; Noorsaadah Abd Rahman; Rozana Othman; Habibah A Wahab
Journal:  PLoS One       Date:  2019-01-24       Impact factor: 3.240

9.  Repurposing the Antiemetic Metoclopramide as an Antiviral Against Dengue Virus Infection in Neuronal Cells.

Authors:  Ting-Jing Shen; Vu Thi Hanh; Thai Quoc Nguyen; Ming-Kai Jhan; Min-Ru Ho; Chiou-Feng Lin
Journal:  Front Cell Infect Microbiol       Date:  2021-02-02       Impact factor: 5.293

10.  An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.

Authors:  Dhiraj Acharya; Fengwei Bai
Journal:  Methods Mol Biol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.